Abstract: Methods are disclosed herein for administering a oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitor for treating autoimmune and/or glomerulonephritis-associated diseases, and in particular, Systemic Lupus Erythematosus (SLE).

Abstract: Disclosed herein are compounds that selectively inhibit members of the PTP family of enzymes. Synthesized compounds demonstrated selective inhibition of TC-PTP. Also provided are methods of using the compounds and formulations containing the compounds. Also described is a fluorescence-tagged combinatorial library synthesis and screening method. And methods of using these compounds to effect enzyme activity both in cells and in vitro as well as method of using these compounds to treat diseases in human and animals.

Abstract: Small molecule compounds derived from ?-sulfophenylacetic amide (SPAA) are provided as novel sulfonic acid based pTyr mimetics. These compounds effectively inhibit a variety of protein tyrosine phosphatases (PTPs), such as mPTPA, mPTPB, LMWPTP, and Laforin. Use of these compounds as pharmaceutical agents for treating diseases associated with abnormal protein tyrosine phosphatase activity is also provided.

Abstract: Small molecule compounds derived from ?-sulfophenylacetic amide (SPAA) are provided as novel sulfonic acid based pTyr mimetics. These compounds effectively inhibit a variety of protein tyrosine phosphatases (PTPs), such as mPTPA, mPTPB, LMWPTP, and Laforin. Use of these compounds as pharmaceutical agents for treating diseases associated with abnormal protein tyrosine phosphatase activity is also provided.

Abstract: Methods are disclosed herein for administering a oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitor for treating autoimmune and/or glomerulonephritis-associated diseases, and in particular, Systemic Lupus Erythematosus (SLE).

Abstract: The present invention provides an isolated synchronous rectification control circuit, a control device, and a control method. The control circuit includes a power supply module, a reference module, a comparator module, a primary side turn-on determination unit, a secondary intermittent burst estimation unit, a logic unit, and a driver unit. The control device includes a transformer, a bypass capacitor configured to provide a stable voltage, a time constant setting resistor configured to configure a primary side turn-on time constant and a secondary intermittent burst time estimation determination, a synchronous rectification control circuit configured to determine the primary side turn-on based on the current flowing into a time setting terminal, predict a secondary side intermittent burst time, and generate logic control signals to drive the turn-on or turn-off of the synchronous rectifier, and an output capacitor connected to the rectification control circuit to provide an output capacitance.

Abstract: Methods are disclosed herein for administering a oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitor for treating autoimmune and/or glomerulonephritis-associated diseases, and in particular, Systemic Lupus Erythematosus (SLE).

Abstract: The present invention provides an isolated synchronous rectification control circuit, a control device, and a control method. The control circuit includes a power supply module, a reference module, a comparator module, a primary side turn-on determination unit, a secondary intermittent burst estimation unit, a logic unit, and a driver unit.

Abstract: Methods are disclosed herein for administering a oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitor for treating autoimmune and/or glomerulonephritis-associated diseases, and in particular, Systemic Lupus Erythematosus (SLE).

Abstract: Inhibitors of protein tyrosine phosphatases are disclosed. The inhibitors include hydroxyindole carboxylic acids having a linker and an amine scaffold that are potent inhibitors of Src homology 2-domain containing protein tyrosine phosphatase-2.

Abstract: A variety of benzofurans and indole derivatives some with an alkynyl linker are disclosed herein. These compounds are not highly charged at physiological pH and have good bioavailability characteristics. These compounds exhibit selective or at least preferential affinity for the active sites of various sub-sets of protein tyrosine phosphatases. Some of these compounds are excellent inhibitors of Mycobacterium protein tyrosine phosphatase B (mPTPB) a protein tyrosine phosphatase expressed in Mycobacterium tuberculosis and characterized as a virulence factor in the causal agent of tuberculosis. Accordingly, many of these compounds and pharmaceutically acceptable salts thereof are useful for the treatment of diseases such as tuberculosis.

Abstract: Embodiments of the present disclosure disclose an interactive method, a client device, a mobile terminal and a server, which relate to an Internet technology field and provide a new way for interacting with a user. The interactive method provided by the present disclosure includes: sending a first request of obtaining first activity information to a server, such that the server obtains the first activity information in local according to the first request of obtaining first activity information, the first activity information comprising an activity entrance icon; receiving the first activity information returned by the server; displaying the activity entrance icon on a user interface of the client device according to the first activity information; receiving an activity participating instruction issued by a user through operating the activity entrance icon; popping up an activity participating result according to the activity participating instruction.

Abstract: Disclosed herein are compounds that selectively inhibit members of the PTP family of enzymes. Synthesized compounds demonstrated selective inhibition of TC-PTP. Also provided are methods of using the compounds and formulations containing the compounds. Also described is a fluorescence-tagged combinatorial library synthesis and screening method. And methods of using these compounds to effect enzyme activity both in cells and in vitro as well as method of using these compounds to treat diseases in human and animals.

Abstract: Novel protein tyrosine phosphatase (PTP) inhibitor compounds synthesized from phosphonodifluoromethyl phenylalanine (F2Pmp) are provided. Use of these compounds for inhibiting a PTP enzyme (such as PTP-MEG2), as well as treating a disease, disorder, or condition associated with inappropriate activity of a PTP (such as type 2 diabetes), is also provided.

Abstract: Inhibitors of protein tyrosine phosphatases are disclosed. The inhibitors include hydroxyindole carboxylic acids having a linker and an amine scaffold that are potent inhibitors of Src homology 2-domain containing protein tyrosine phosphatase-2.

Abstract: Disclosed herein are compounds that selectively inhibit members of the PTP family of enzymes. Synthesized compounds demonstrated selective inhibition of TC-PTP. Also provided are methods of using the compounds and formulations containing the compounds. Also described is a fluorescence-tagged combinatorial library synthesis and screening method. And methods of using these compounds to effect enzyme activity both in cells and in vitro as well as method of using these compounds to treat diseases in human and animals.

Abstract: A mounting apparatus for securing a battery module to an enclosure includes a bracket and a latching member. The bracket is secured to the enclosure and defines a receiving space for receiving the battery module. The latching member is attached to the bracket and includes a resilient portion and a blocking flange perpendicularly connected to the resilient portion. The blocking flange is engaged with the battery module to prevent the battery module from disengaging from the receiving space, and the resilient portion is resiliently deformable to disengage the blocking flange from the battery module so that the battery module is easily installed or detached from the enclosure without extra tools.

Abstract: An induction device includes a frame, a first conductive assembly, and a sliding assembly. The frame is configured to be secured to a rack. The first conductive assembly is located in the frame. The sliding assembly is mounted in the frame and includes a second conductive assembly. The second conductive assembly is slidable relative to the frame and electronically couples to the first conductive assembly during sliding, and the second conductive assembly is configured to electronically couple to a detection module during sliding. An electronic device with the induction device is further disclosed.

Abstract: Novel protein tyrosine phosphatase (PTP) inhibitor compounds synthesized from phosphonodifluoromethyl phenylalanine (F2Pmp) are provided. Use of these compounds for inhibiting a PTP enzyme (such as PTP-MEG2), as well as treating a disease, disorder, or condition associated with inappropriate activity of a PTP (such as type 2 diabetes), is also provided.

Abstract: An electronic device includes a chassis and a tray installed in the chassis. The tray includes a base plate which defines an opening. A limiting standoff protrudes from an inner surface of the chassis and extends through the opening of the base plate. A locking module includes a pivotable member pivotally attached to the base plate which rotates about an axis perpendicular to the base plate. When the pivotable member is rotated to a first position, the limiting standoff locks the pivotable member to prevent the tray from sliding out from the chassis. When the pivotable member is rotated to a second position, the limiting standoff unlocks the pivotable member to allow the tray sliding out from the chassis.